These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8727809)

  • 1. Nursing implications in the management of superficial bladder cancer.
    Games J
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):36-40. PubMed ID: 8727809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical Bacillus Calmette-Guerin for treating bladder cancer.
    Boyd LA
    Urol Nurs; 2003 Jun; 23(3):189-91, 199; quiz 192. PubMed ID: 12861735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
    Huben RP
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications of intravesical therapy for urothelial cancer of the bladder.
    Koya MP; Simon MA; Soloway MS
    J Urol; 2006 Jun; 175(6):2004-10. PubMed ID: 16697786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
    Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
    Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical antineoplastic therapy following transurethral resection of bladder tumors: nursing implications from the operating room to discharge.
    Washburn DJ
    Clin J Oncol Nurs; 2007 Aug; 11(4):553-9. PubMed ID: 17723968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.
    Punnen SP; Chin JL; Jewett MA
    Can J Urol; 2003 Apr; 10(2):1790-5. PubMed ID: 12773228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is intravesical chemotherapy for superficial bladder cancer still justified?
    Okeke AA; Probert JL; Gillatt DA; Schwaibold H
    BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
    [No Abstract]   [Full Text] [Related]  

  • 20. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A; Sezian N; Thwaini A
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.